Posted by Michael Wonder on 02 Mar 2023
Checkpoint Therapeutics announces FDA filing acceptance of biologics license application for cosibelimab in metastatic or locally advanced cutaneous squamous cell carcinoma
2 March 2023 - PDUFA goal date of 3 January 2024.
Checkpoint Therapeutics today announced that the US FDA has accepted for filing the biologics license application for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
